Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents

K. W. Pankiewicz

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Inosine monophosphate dehydrogenase (IMPDH, E.C., an NAD-dependent enzyme that controls de novo synthesis of purine nucleotides, is an important target for the development of chemotherapeutic agents. The concentration of IMPDH is known to increase in tumour cells and activated lymphocytes. Thus, inhibition of IMPDH should result in anticancer and immunosuppressive activities. Since there is an increased demand for purine nucleotides in virus-infected cells needed for RNA and DNA synthesis, inhibition of IMPDH may also lead to antiviral activity. IMPDH enzymes from bacteria, parasites and mammalian sources differ significantly. Such differences can be exploited for the development of antibacterial or antiparasitic agents. A review, which covers the development of the field up to 1998, was published in this Journal [Pankiewicz KW, Expert Opin. Ther. Patents (1999) 9(1):55-65]. This article describes recent studies of molecular structure, mechanism of action and interactions of the enzyme with the co-factor and inhibitors. Perspectives on the development of a new generation of potent and specific inhibitors of IMPDH based on these accomplishments are discussed.

Original languageEnglish (US)
Pages (from-to)1161-1170
Number of pages10
JournalExpert Opinion on Therapeutic Patents
Issue number7
StatePublished - 2001
Externally publishedYes


  • Antiviral
  • Cancer
  • Chemotherapy
  • Immunosuppression


Dive into the research topics of 'Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents'. Together they form a unique fingerprint.

Cite this